PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Metsä Board Oyj (METSA.HE)
5.580.04 (-0.71%)
5.38 - 5.60
4.95 - 8.28
2.3K / 2.4K (Avg.)
-279.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.54%
Positive revenue growth while UPM.HE is negative. John Neff might see a notable competitive edge here.
-5.90%
Negative gross profit growth while UPM.HE is at 2.71%. Joel Greenblatt would examine cost competitiveness or demand decline.
-8.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-8.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-10.47%
Negative net income growth while UPM.HE stands at 0.82%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-8.60%
Negative EPS growth while UPM.HE is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-8.60%
Negative diluted EPS growth while UPM.HE is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-2.06%
Share reduction while UPM.HE is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.06%
Reduced diluted shares while UPM.HE is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
42.67%
OCF growth above 1.5x UPM.HE's 14.68%. David Dodd would confirm a clear edge in underlying cash generation.
99.25%
FCF growth above 1.5x UPM.HE's 16.95%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-29.49%
Negative 10Y revenue/share CAGR while UPM.HE stands at 26.72%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-4.39%
Negative 5Y CAGR while UPM.HE stands at 2.96%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
16.34%
3Y revenue/share CAGR above 1.5x UPM.HE's 2.00%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-41.77%
Negative 10Y OCF/share CAGR while UPM.HE stands at 57.76%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-14.26%
Negative 5Y OCF/share CAGR while UPM.HE is at 66.23%. Joel Greenblatt would question the firm’s operational model or cost structure.
-31.60%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
138.09%
Below 50% of UPM.HE's 502.02%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
56.90%
5Y net income/share CAGR above 1.5x UPM.HE's 35.36%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
82.83%
Positive short-term CAGR while UPM.HE is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
52.58%
5Y equity/share CAGR above 1.5x UPM.HE's 27.57%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
35.39%
3Y equity/share CAGR 1.25-1.5x UPM.HE's 23.96%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.70%
Firm’s AR is declining while UPM.HE shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-3.27%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-0.08%
Negative asset growth while UPM.HE invests at 2.44%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.61%
1.25-1.5x UPM.HE's 3.12%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-1.14%
We’re deleveraging while UPM.HE stands at 4.11%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-12.62%
We cut SG&A while UPM.HE invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.